DexCom, Inc. $DXCM Shares Sold by Shell Asset Management Co.

Shell Asset Management Co. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 77.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,936 shares of the medical device company’s stock after selling 27,876 shares during the quarter. Shell Asset Management Co.’s holdings in DexCom were worth $534,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. GAMMA Investing LLC grew its position in DexCom by 2.5% during the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after buying an additional 169 shares during the period. Inspire Investing LLC raised its position in shares of DexCom by 6.1% in the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock valued at $211,000 after buying an additional 180 shares during the last quarter. Inspire Advisors LLC lifted its stake in shares of DexCom by 2.5% during the 3rd quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock worth $533,000 after purchasing an additional 194 shares during the period. Integrated Wealth Concepts LLC lifted its position in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares during the period. Finally, STF Management LP lifted its holdings in shares of DexCom by 5.5% during the 2nd quarter. STF Management LP now owns 4,041 shares of the medical device company’s stock worth $353,000 after acquiring an additional 211 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DXCM has been the topic of a number of research analyst reports. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Sanford C. Bernstein reissued an “outperform” rating and set a $86.00 target price (up from $84.00) on shares of DexCom in a research report on Friday, January 9th. Citigroup reissued a “buy” rating and issued a $77.00 price target (up previously from $75.00) on shares of DexCom in a report on Thursday, December 11th. Leerink Partners reissued an “outperform” rating and set a $92.00 price objective on shares of DexCom in a report on Tuesday, December 16th. Finally, TD Cowen decreased their target price on DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.18.

DexCom Stock Performance

Shares of DXCM opened at $70.43 on Wednesday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $27.11 billion, a PE ratio of 33.54, a P/E/G ratio of 1.25 and a beta of 1.49. The firm has a 50-day moving average price of $69.20 and a 200 day moving average price of $69.33.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 earnings per share. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.